Scribe Stock
Scribe Therapeutics is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.
Sign up for SecondMarket™ to view the market and buy or sell Scribe Stock
Buy + SellScribe Funding
Sign up to gain insights into Scribe funding history, including the funding round, time period, and amount raised.
Sign Up to Unlock the DataDate | Financing Round | Amount | Price per share* | Valuation* |
---|---|---|---|---|
Mar 17, 2021 | Series B | 100.00M | ||
Jan 30, 2019 | Series A | 500.00K | ||
Oct 01, 2018 | Series A | 205.40K | ||
Oct 01, 2018 | Series A | 20.00M |
See Scribe Valuations + Financials
*Sample data + company shown for illustrative purposes only
Gain insights Into Scribe Stock Valuation + Share Prices
View real-time Tape D™ data on Scribe stock including most recent valuation and historical share price information.
Are you an institutional investor or employee shareholder? Sign up to the SecondMarket™ trading platform.
Get Started